Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 140.48 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; croscarmellose sodium; magnesium stearate; calcium hydrogen phosphate dihydrate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - tigerfil sandoz pharma is indicated for the treatment of erectile dysfunction in adult males. tigerfil sandoz pharma is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 35.121 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 140.483 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 70.241 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; purified water; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sildenafil citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sildenafil citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 35.1 mg (equivalent: sildenafil, qty 25 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; copovidone; microcrystalline cellulose; saccharin sodium; calcium hydrogen phosphate; croscarmellose sodium - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil is indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [see clinical studies (14)] . studies establishing effectiveness were short-term (12 to 16 weeks), included predominately patients with new york heart association (nyha) functional class ii–iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). limitation of use : adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see clinical studies (14)] . sildenafil is contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - known hypersensitivity to sildenafil or any component of the tablet. hypersensitivity, inc